195 related articles for article (PubMed ID: 34809504)
21. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology?
Pavlovic M; Garnier J; Durand-Zaleski I; ; Bilbault P; Gaudin AF; Le Jeunne C; Lalaude O; Roze S; de Sahb R; Sapède C
Therapie; 2016 Dec; 71(6):625-632. PubMed ID: 27639631
[TBL] [Abstract][Full Text] [Related]
23. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
25. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
26. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
Appiah K; Rizzo M; Sarri G; Hernandez L
J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
[No Abstract] [Full Text] [Related]
27. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
28. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
29. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
30. A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies.
Stevens W; Philipson T; Wu Y; Chen C; Lakdawalla D
Forum Health Econ Policy; 2014 Jan; 17(1):21-52. PubMed ID: 31419878
[TBL] [Abstract][Full Text] [Related]
31. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
Front Public Health; 2022; 10():964040. PubMed ID: 36187695
[TBL] [Abstract][Full Text] [Related]
32. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
[TBL] [Abstract][Full Text] [Related]
33. New trends and challenges in the European regulation of innovative medicines.
Enzmann H
Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
[TBL] [Abstract][Full Text] [Related]
34. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F; Goettsch WG; Mantel-Teeuwisse AK; Bloem LT
BMJ; 2024 Feb; 384():e077391. PubMed ID: 38418086
[TBL] [Abstract][Full Text] [Related]
35. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
Chabot I; Rocchi A
Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
[TBL] [Abstract][Full Text] [Related]
36. Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.
Ciani O; Grigore B; Blommestein H; de Groot S; Möllenkamp M; Rabbe S; Daubner-Bendes R; Taylor RS
Med Decis Making; 2021 May; 41(4):439-452. PubMed ID: 33719711
[TBL] [Abstract][Full Text] [Related]
37. A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
Chassany O; Engen AV; Lai L; Borhade K; Ravi M; Harnett J; Chen CI; Quek RG
Future Oncol; 2022 Sep; 18(29):3323-3334. PubMed ID: 36053168
[TBL] [Abstract][Full Text] [Related]
38. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
[TBL] [Abstract][Full Text] [Related]
39. A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
Allen N; Liberti L; Walker SR; Salek S
Front Pharmacol; 2017; 8():384. PubMed ID: 28713265
[No Abstract] [Full Text] [Related]
40. Do France, Germany, and Italy agree on the added therapeutic value of medicines?
Casilli G; Lidonnici D; Jommi C; De Nigris M; Genazzani AA
Int J Technol Assess Health Care; 2023 Aug; 39(1):e54. PubMed ID: 37580971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
